Impax Pharmaceuticals Announces IPX066 Demonstrates Efficacy and Safety in APEX-PD Phase III Study in Treatment of Early Parkinson's Disease

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced positive top-line results of the APEX-PD Phase III clinical study with IPX066 in Parkinson’s disease (PD). IPX066 is a novel extended release carbidopa-levodopa product. The APEX-PD results demonstrate that IPX066 is safe and efficacious when used in patients with early Parkinson’s disease.